The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the
treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice …

Kidney injury caused by immunoglobulin free light chains (FLCs) in the setting of plasma cell
dyscrasias is common and associated with increased morbidity and mortality. All …

Comorbidities have been demonstrated to affect progression-free survival (PFS) and overall
survival (OS), although their impact in multiple myeloma (MM) patients is as yet unsettled …

As doenças cardiovasculares nos pacientes com câncer são eventos cada vez mais
frequentes, em decorrência de avanços na terapêutica oncológica que resultaram tanto na …

Despite recent therapeutic advancements, multiple myeloma (MM) remains incurable and
new therapies are needed, especially for the treatment of elderly and relapsed/refractory …

Up to 50% of newly diagnosed plasma cell myeloma (PCM) patients can present with renal
insufficiency, 20% with severe renal impairment and 10% requiring dialysis. PCM patients …

The current standard of care for elderly patients with newly diagnosed multiple myeloma is
melphalan and prednisone (MP) in combination with either bortezomib (VMP) or thalidomide …

Renal impairment (RI) is a common presenting complication of multiple myeloma associated
with significant morbidity and early mortality, while it has been associated with inferior …

Kidney dysfunction is a common clinical feature of symptomatic multiple myeloma. Some
degree of renal insufficiency or renal failure is present at diagnosis or will occur during the …

The article discusses the effectiveness of bendamustine, thalidomide, and dexamethasone
as therapy for myeloma patients with end stage renal disease. It states that myeloma …